The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARWR | +179.79% | -0.96% | -0.19% | +24% |
| S&P | +12.66% | +85.37% | +13.13% | +512% |
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
These are historic days for the company, following its first FDA approval.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $256.47M | 0.0% |
| Gross Profit | $250.09M | 5076.8% |
| Gross Margin | 97.51% | 0.0% |
| Market Cap | $4.77B | 98.0% |
| Market Cap / Employee | $6.71M | 0.0% |
| Employees | 711 | 16.7% |
| Net Income | $16.12M | 109.3% |
| EBITDA | $50.49M | 132.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $226.55M | 120.6% |
| Accounts Receivable | $6.82M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $686.39M | -18.8% |
| Short Term Debt | $47.29M | 645.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.13% | 62.8% |
| Return On Invested Capital | -35.41% | -17.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $13.00M | 108.1% |
| Operating Free Cash Flow | $20.49M | 114.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 12.61 | 30.42 | 3.19 | 9.12 | 25.31% |
| Price to Sales | 938.86 | 3.14 | 3.83 | 5.64 | -99.17% |
| Price to Tangible Book Value | 13.22 | 35.99 | 3.23 | 9.25 | 23.63% |
| Price to Free Cash Flow TTM | 372.79 | 29.83 | - | ||
| Enterprise Value to EBITDA | -17.09 | 3.50 | -12.60 | 89.76 | -645.61% |
| Free Cash Flow Yield | 0.3% | 3.4% | - | ||
| Return on Equity | -600.7% | -24.7% | -34.8% | -0.5% | -99.81% |
| Total Debt | $872.05M | $740.51M | $713.29M | $733.68M | -13.88% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
